United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Stocks in this Quantisnow insightHealth Care
Historical context for UTHR
Across the 28 sessions after earlier UTHR headlines, the stock closed higher 17 times and lower 11 times, with a median move of 1.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | UTHR | SPY |
|---|---|---|---|
| Oct 21, 2026 | United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 | +1.7% | +0.5% |
| Oct 20, 2026 | United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility | +2.0% | +0.3% |
| Oct 19, 2026 | United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD | +1.9% | +0.4% |
| Oct 13, 2026 | United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting | -1.2% | -0.0% |
| Oct 1, 2026 | United Therapeutics upgraded by BTIG Research with a new price targetand 1 other headline that session | +5.4% | +0.2% |
| Sep 24, 2026 | Goldman initiated coverage on United Therapeutics with a new price target | -3.5% | -0.1% |
Keep researching UTHR
- UTHR insider tradesEvery buy and sale reported by United Therapeutics Corporation officers, directors and large holders.
- UTHR earnings historyPast United Therapeutics Corporation earnings releases, newest first.
- UTHR financial statementsRevenue, profit, cash flow and balance sheet from United Therapeutics Corporation's SEC filings.
Quantisnow market dataNASDAQ
UTHR
United Therapeutics Corporation
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 1999
Get push alerts for UTHR
Full UTHR profile on Quantisnow Follow UTHR and get a push notification the moment its next story breaks.